Antony Mattessich
Net Worth
Last updated:
What is Antony Mattessich net worth?
The estimated net worth of Mr. Antony Mattessich is at least $15,656,460 as of 5 Feb 2024. He owns shares worth $7,146,830 as insider, has earned $269,630 from insider trading and has received compensation worth at least $8,240,000 in Ocular Therapeutix, Inc..
What is the salary of Antony Mattessich?
Mr. Antony Mattessich salary is $1,030,000 per year as Pres, Chief Executive Officer & Director in Ocular Therapeutix, Inc..
How old is Antony Mattessich?
Mr. Antony Mattessich is 58 years old, born in 1967.
What stocks does Antony Mattessich currently own?
As insider, Mr. Antony Mattessich owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Ocular Therapeutix, Inc. (OCUL) | Pres, Chief Executive Officer & Director | 588,701 | $12.14 | $7,146,830 |
What does Ocular Therapeutix, Inc. do?
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Antony Mattessich insider trading
Ocular Therapeutix, Inc.
Mr. Antony Mattessich has made 3 insider trades between 2017-2024, according to the Form 4 filled with the SEC. Most recently he sold 19,642 units of OCUL stock worth $95,460 on 5 Feb 2024.
The largest trade he's ever made was exercising 40,000 units of OCUL stock on 6 Jun 2019. As of 5 Feb 2024 he still owns at least 588,701 units of OCUL stock.
Ocular Therapeutix key executives
Ocular Therapeutix, Inc. executives and other stock owners filed with the SEC:
- Dr. Michael H. Goldstein M.M., M.D., M.B.A. (58) Pres of Ophthalmology & Chief Medical Officer
- Mr. Antony Mattessich (58) Pres, Chief Executive Officer & Director
- Mr. Philip C. Strassburger (65) Gen. Counsel